Medicine and Dentistry
Angiosarcoma
100%
Neoplasm
46%
Radiation Therapy
40%
Retrospective Cohort Study
33%
Cerebral Hemorrhage
33%
Hemangioendothelioma
33%
Early Intervention
33%
Lung
33%
Brain Metastasis
33%
Scalp
33%
Bleeding
26%
Diseases
23%
Progression Free Survival
20%
Overall Survival
20%
Pembrolizumab
20%
Prognostic Factor
16%
Disease Specific Survival
16%
Systemic Therapy
13%
Monotherapy
13%
Anemia
13%
Platelet
10%
Neck
8%
Proportional Hazards Model
8%
Retrospective Study
6%
Cancer
6%
Bone Marrow Biopsy
6%
Lung Biopsy
6%
Recurrent Disease
6%
Magnetic Resonance Imaging
6%
Immunotherapy
6%
Epigastric Pain
6%
Exanthem
6%
Extramedullary Hematopoiesis
6%
Constipation
6%
Histopathology
6%
Iron
6%
Hematology
6%
Patient-Data
6%
Population Research
6%
Vascular Tissue Neoplasm
6%
Disease Exacerbation
6%
Splenomegaly
6%
Combination Therapy
6%
Fibrosis
6%
Metastatic Carcinoma
6%
Myeloproliferative Neoplasm
6%
Malignant Neoplasm
6%
Keyphrases
Definitive Treatment
33%
Radiation Therapy
33%
Bone Marrow
33%
Liver
33%
Kaposiform Hemangioendothelioma
33%
Cutaneous Angiosarcoma
33%
Adult-onset
33%
Lung
33%
Scalp
33%
Surgery Therapy
33%
Terminal Haemorrhage
26%
Single Modality
16%
Prognostic Factors
16%
Disease-specific Survival
16%
Multifocal Tumors
16%
Multivariable
16%
Retrospective Review
8%
Head-and-neck
8%
Large Tumors
8%
Kaplan-Meier
8%
Cox Proportional Hazards Model
8%
Patient with Tumor
8%
Improved Outcomes
8%
Tumor Size
8%
Lung Biopsy
6%
Bone Marrow Biopsy
6%
Anemia
6%
Caucasian Women
6%
Abdominal
6%
Indolent Behavior
6%
Extramedullary Hematopoiesis
6%
Rare Forms
6%
Iron Deposition
6%
Vascular Neoplasms
6%
Epigastric Pain
6%
Duration Control
6%
Imaging Findings
6%
Neoplasms
6%
Magnetic Resonance Imaging
6%
Fibrosis
6%
Multi-focus
6%
Myeloproliferative Neoplasms
6%
Chief Complaint
6%
Pathological Findings
6%
Malignancy
6%
Tissue-mimicking
6%
Aggressive Disease
6%
Splenomegaly
6%
Hematology
6%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
33%
Angiosarcoma
33%
Pembrolizumab
20%
Progression Free Survival
20%
Overall Survival
20%
Monotherapy
13%
Diseases
13%
Constipation
6%
Population Study
6%
Retrospective Study
6%
Recurrent Disease
6%
Malignant Neoplasm
6%
Systemic Treatment
6%
Anemia
6%
Metastasis
6%
Rash
6%
Disease Exacerbation
6%
Combination Therapy
6%
Immunotherapy
6%
Neoplasm
6%